A critical role for Fc gamma RIIB in the induction of rheumatoid factors.
Rheumatoid factors (RF) are autoantibodies with specificity for the Fc portion of IgG, and IgG-containing immune complexes are likely to be the major source of RF autoantigens. Therefore, the activation of RF-producing B cells could be controlled specifically through recognition of IgG immune complexes by the low-affinity IgG FcR, FcgammaRIIB, a potent negative regulator of the BCR. To test this possibility, we determined the development of RF in C57BL/6 (B6) mice lacking FcgammaRIIB, in relation to the H2 haplotype, complement C3, and the Y-linked autoimmune acceleration (Yaa) mutation. FcgammaRIIB-null B6 mice displayed substantial anti-IgG2a RF activities in their sera, in addition to anti-DNA autoantibodies. Their RF and anti-DNA responses were linked to the H2(b) haplotype, but were suppressed almost completely by the H2(d) haplotype. Strikingly, the absence of C3 failed to modulate RF production, but strongly inhibited anti-DNA production. Furthermore, we observed that partial FcgammaRIIB deficiency (i.e., heterozygous level of FcgammaRIIB expression) was sufficient to induce the production of RF and anti-DNA autoantibodies in the presence of the Yaa mutation. In contrast to FcgammaRIIB, the deficiency in another BCR negative regulator, CD22, was unable to promote RF and anti-DNA autoimmune responses in B6 mice. Our results indicate that RF autoimmune responses are critically controlled by FcgammaRIIB, together with the H2(b) and Yaa gene, while C3 regulates positively and specifically anti-DNA, but not RF autoimmune responses.
Moll
Thomas
T
Department of Pathology and Immunology, Centre Médical Universitaire, Geneva, Switzerland.
Nitschke
Lars
L
Carroll
Michael
M
Ravetch
Jeffrey V
JV
Izui
Shozo
S
D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis / Q000097:blood; D015703:Antigens, CD / Q000235:genetics / Q000502:physiology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000235:genetics; D015815:Cell Adhesion Molecules / Q000172:deficiency / Q000235:genetics; D002478:Cells, Cultured; D003176:Complement C3 / Q000172:deficiency / Q000235:genetics; D004247:DNA / Q000276:immunology; D005260:Female; D008040:Genetic Linkage / Q000276:immunology; D006183:H-2 Antigens / Q000502:physiology; D007165:Immunosuppression Therapy / Q000379:methods; D037102:Lectins / Q000172:deficiency / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation; D017452:Receptors, IgG / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D012217:Rheumatoid Factor / Q000096:biosynthesis*; D051918:Sialic Acid Binding Ig-like Lectin 2; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014998:Y Chromosome / Q000235:genetics / Q000276:immunology
D000974:Antibodies, Antinuclear; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C497868:Cd22 protein, mouse; D015815:Cell Adhesion Molecules; D003176:Complement C3; C080571:Fc gamma receptor IIB; D006183:H-2 Antigens; D037102:Lectins; D017452:Receptors, IgG; D051918:Sialic Acid Binding Ig-like Lectin 2; D004247:DNA; D012217:Rheumatoid Factor